


**13 February 2023**

## Nifty Intraday Chart



## Market in Retrospect

Indian equity benchmarks declined amid weak Asia trade on Monday as investors await inflation data.

Nifty index ended 0.48% lower, ended at 17,771. The broader markets represented by the Nifty 500 Index ended 0.77% lower, ending at 14,901. Among the sectorial indices, Nifty PSE was the top gainer gaining by 0.28%, followed by Nifty FMCG gaining by 0.04%. Nifty PSU Bank was the top loser losing by 2.52%.

Titan was the top gainer, gaining by 2.05%, followed by L&T and NTPC which gaining by 1.82% & 1.73%. Adani Enterprises was the top loser, losing by 7%, followed by Adani Ports & SE and SBI losing by 5.18% & 2.81%.

## Market Turnover (In Crore) 13-02-2023

Name	Last	Previous
NSE Cash	45840.09	46251.52
NSE F&O	11944019.04	8057896.34
BSE Cash	2,875.80	2,918.27
BSE F&O	*NA	115.37

## FII Derivatives Flow (In Crore) 13-02-2023

Instrument	Purchase	Sale	Net
Index Future	3916.55	4837.48	-920.93
Index Option	555276.34	557810.49	-2534.15
Stock Future	9891.99	10478.65	-586.66
Stock Option	11336.00	11474.77	-138.77

## Institutional Flow (In Crore) 13-02-2023

Institution	Purchase	Sale	Net
FII	7386.63	6064.24	1322.39
DII	5361.52	4839.83	521.69

## NIFTY Top Gainers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
Titan	2.05	2.48	1856317	642681
Larsen & Toubro	1.82	2.19	2978938	1378345
NTPC	1.73	1.08	9829152	8020875
Bajaj Auto	1.35	0.89	372862	236044
Eicher Motors	1.25	0.25	405135	353065

## NIFTY Top Losers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
TCS	1.56	0.65	1087939	1484911
Infosys	2.56	0.15	4001199	5716372
SBI	2.81	1.45	18488732	17184580
Adani Ports & SE	5.18	1.51	19528545	30229550
Adani Enterprises	7.00	9.22	12210940	17456880

## Bulk and Block Deals

<https://www.nseindia.com/products/content/equities/equities/bulk.htm>  
<http://www.bseindia.com/markets/equity/EQReports/BulknBlockDeals.aspx>

\*Data not updated till 7:30PM



## Sensex Intraday Chart



## Market in Detailed (Updated after 4:00 PM)

### Indian Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Sensex	60431.84	250.86	0.41	0.12	0.28	1.93	7.14
Nifty	17770.90	85.60	0.48	0.04	1.03	3.05	5.51
BSE M Cap	24580.36	310.08	1.25	0.21	2.35	3.47	1.36
BSE S Cap	27932.15	330.90	1.17	0.24	3.21	3.63	2.65
Nifty MC 100	30565.35	464.10	1.50	0.34	2.44	2.66	7.03
BSE Auto	30199.07	185.84	0.61	1.08	2.64	0.99	19.91
BSE Capgoods	34747.25	193.06	0.56	1.72	1.75	4.70	26.19
BSE FMCG	16402.72	6.91	0.04	1.57	2.59	1.20	21.44
BSE Metal	20035.70	30.88	0.15	2.50	6.69	2.00	0.15
BSE Oil&Gas	17483.41	82.64	0.47	0.93	15.21	12.44	1.70
BSE Healthcare	22293.53	147.46	0.66	0.36	3.35	5.75	8.49
BSE Power	3479.10	21.54	0.62	2.99	21.44	27.88	7.42
BSE Realty	3267.46	59.02	1.77	0.02	3.90	9.46	5.95
BSE ConsDur	38640.56	0.89	0.00	0.10	0.13	7.07	5.89
BSE Bank	46672.75	328.85	0.70	0.28	3.09	2.88	10.56
BSE IT	30153.19	578.93	1.88	0.28	4.14	1.46	12.02

### Bond Markets

Name	Yield	Net Chng	%1D	%5D	%1M	%3M	%1Y
US	3.74	0.01	0.21	2.74	6.74	1.91	93.06
UK	3.43	0.03	0.97	5.70	1.87	2.11	121.94
Brazil	6.36	0.10	1.52	4.57	6.78	0.56	26.85
Japan	0.51	0.01	1.79	1.19	0.20	111.16	121.21
Australia	3.76	0.05	1.43	8.61	4.68	2.87	70.09
India	7.37	0.00	0.03	0.29	0.89	0.78	9.96
Switzerland	1.41	0.00	0.14	7.79	25.65	27.92	327.58
Germany	2.38	0.01	0.47	3.44	9.55	9.95	699.66

### Currency

Name	Rate	Net Chng	%1D	%5D	%1M	%3M	%1Y
INR	82.73	0.22	0.27	0.01	1.68	1.77	8.61
USD Index	103.50	0.13	0.13	0.12	1.27	2.63	7.72
YUAN	6.82	0.01	0.14	0.41	1.81	3.59	6.84
GBP	1.21	0.00	0.32	0.67	1.04	2.93	10.56
EUR	1.07	0.00	0.10	0.35	1.30	3.51	5.47
YEN	132.55	1.19	0.90	0.08	3.53	5.54	12.83

### Freight

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Baltic Dry	602.00	10.00	1.69	0.99	36.36	55.57	69.55
Baltic Dirty	1206.00	1.00	0.08	1.47	16.54	36.33	75.55
SG Dubai HY	25.48	2.40	10.40	18.81	23.37	24.22	638.25

### Global Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Dow Jones	33869.27	169.39	0.50	0.17	1.26	0.36	2.50
Nasdaq	11718.12	71.46	0.61	2.41	5.77	3.49	15.03
S&P 500	4090.46	8.96	0.22	1.11	2.28	2.44	7.43
FTSE100	7915.22	33.21	0.42	1.01	0.91	8.17	3.32
CAC40	7188.01	58.79	0.82	0.72	2.35	9.01	2.52
DAX	15373.13	65.67	0.43	0.18	1.90	8.08	0.33
Mexico IPC	52482.02	319.41	0.60	2.59	2.04	1.01	1.40
Brazil Bovespa	108078.3	70.22	0.07	0.41	2.56	3.72	4.84
Russian RTS	970.61	1.66	0.17	3.66	3.97	16.23	34.00
Japan Nikkei	27427.32	243.66	0.88	0.96	5.01	1.92	1.28
Hang Seng	21164.42	26.00	0.12	0.27	2.64	20.12	13.81
Taiwan Index	15544.28	42.37	0.27	0.98	4.86	9.66	13.63
Shanghai Comp	3284.16	23.49	0.72	1.40	2.78	6.51	4.22
KOSPI	2452.70	17.03	0.69	0.60	2.79	0.89	9.31
Malaysia KLCI	1475.17	0.58	0.04	1.03	1.33	0.76	6.86
Jakarta Comp	6900.14	19.81	0.29	0.38	3.89	1.70	2.46
Philippine SE	6838.76	38.03	0.55	1.41	1.62	7.62	7.10
Thai Exch	1664.89	0.32	0.02	1.02	1.00	2.56	1.18

### Indian Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
NYMEX Crude	79.67	0.01	0.01	7.56	0.19	10.40	14.38
BRENT Crude	86.34	0.00	0.00	6.67	0.98	5.77	4.03
Natural Gas	2.56	0.05	1.91	4.27	19.84	52.28	36.27

### LME

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Gold(\$/Ounce)	1860.12	5.75	0.31	0.41	3.15	5.00	0.06
Silver(\$/Ounce)	22.00	0.01	0.04	1.23	9.35	1.34	6.74
Aluminium	2404.74	58.11	2.36	5.12	1.00	4.11	26.39
Copper	8828.76	123.48	1.38	1.37	0.69	6.60	14.33
Zinc	3059.75	92.25	2.93	6.42	3.60	5.53	17.45
Lead	2068.75	57.50	2.70	0.74	6.53	1.46	9.69

### Agro Commodities

Name	Price	Net Chng	%1D	%5D	%1M	%3M	%1Y
Coffee	174.45	0.20	0.11	0.77	14.36	4.15	27.37
Cotton	85.97	0.39	0.46	2.21	4.08	0.48	13.21
Sugar	19.83	0.21	1.05	1.69	7.71	6.61	12.99
Wheat	789.50	6.25	0.79	3.61	4.99	6.73	1.03
Soybean	1544.25	1.75	0.11	1.51	1.08	6.23	9.46

**Gujarat Gas**

Net profit of Gujarat Gas rose 204.49% to Rs 371.26 crore in the quarter ended December 2022 as against Rs 121.93 crore during the previous quarter ended December 2021. Sales declined 28.38% to Rs 3684.29 crore in the quarter ended December 2022 as against Rs 5144.43 crore during the previous quarter ended December 2021.

**Borosil Renewables**

Net profit of Borosil Renewables declined 50.86% to Rs 22.47 crore in the quarter ended December 2022 as against Rs 45.73 crore during the previous quarter ended December 2021. Sales declined 4.23% to Rs 161.39 crore in the quarter ended December 2022 as against Rs 168.51 crore during the previous quarter ended December 2021.

**HBL Power Systems**

Net profit of HBL Power Systems declined 4.43% to Rs 23.74 crore in the quarter ended December 2022 as against Rs 24.84 crore during the previous quarter ended December 2021. Sales declined 4.66% to Rs 332.49 crore in the quarter ended December 2022 as against Rs 348.74 crore during the previous quarter ended December 2021.

**ISGEC Heavy Engineering**

Net profit of ISGEC Heavy Engineering rose 33.87% to Rs 62.96 crore in the quarter ended December 2022 as against Rs 47.03 crore during the previous quarter ended December 2021. Sales rose 14.44% to Rs 1597.06 crore in the quarter ended December 2022 as against Rs 1395.58 crore during the previous quarter ended December 2021.

**Wockhardt**

Net Loss of Wockhardt reported to Rs 96.00 crore in the quarter ended December 2022 as against net loss of Rs 7.00 crore during the previous quarter ended December 2021. Sales declined 18.15% to Rs 699.00 crore in the quarter ended December 2022 as against Rs 854.00 crore during the previous quarter ended December 2021.

**HeidelbergCement India**

HeidelbergCement India Ltd reported an 81.66 per cent decline in its net profit at Rs 5.58 crore in the third quarter ended December 2022, on account of an increase in operating cost. The company had reported a net profit of Rs 30.44 crore in the October-December quarter period a year ago. Its revenue from operation was flat at Rs 540.12 crore during the quarter under review as against Rs 544.52 crore in the corresponding quarter previous fiscal. The firm's total expenses were at Rs 542.67 crore, up 5.52 per cent in Q3FY23.

### **Natco Pharma submits application with USFDA for generic cancer drug**

Natco Pharma has submitted a new application with the US health regulator for marketing authorisation of the generic version of Olaparib tablets, used in treating certain forms of ovarian, breast, pancreatic and prostate cancers. The company has submitted an Abbreviated New Drug Application (ANDA) containing a 'paragraph IV' certification with the US Food and Drug Administration (FDA) for the product, a generic version of AstraZeneca's Olaparib tablets in strengths of 100mg and 150mg. Olaparib tablets are marketed in the US by AstraZeneca under brand Lynparza. Natco Pharma said it has been named as defendant in a lawsuit filed in the US district court of New Jersey by AstraZeneca and Kudos Pharmaceuticals.

### **JSW Steel crude steel output surges 15 pc in Jan**

JSW Steel on Monday reported a 15 per cent rise in crude steel production at 18.91 lakh tonnes in January. The company's crude steel production was at 16.46 lakh tonnes (LT) in January 2022. The production of its flat-rolled products increased by 14 per cent to 14.24 LT over 12.47 LT in January 2022. Its output of long-rolled products also registered a growth of 14 per cent to 4.25 LT, as against 3.74 LT in January 2022. The overall capacity utilisation was higher at 99 per cent in January 2023 from 96 per cent in December 2022. JSW Steel is the flagship business of the diversified USD 22 billion JSW Group which also has business interests in sectors such as energy, infrastructure, cement, paints, sports and venture capital.

### **Lux Industries to achieve turnover of Rs 1,000 crore by FY26**

Lux Industries, a leading knitwear brand, has undertaken a three-pronged strategy to achieve a turnover of Rs 1,000 crore by FY26. The company had clocked a turnover of Rs 550 crore in FY22 and has been growing at a rate of 10% -12% over the last three years.

### **Welspun One Logistics Parks inks pact with UP govt to invest Rs 2,000 cr**

Welspun One Logistics Parks has signed a pact with the Uttar Pradesh government for investment of Rs 2,000 crore to develop warehousing and logistics parks in the state. In a statement, the company said it has signed a Memorandum of Understanding (MoU) with the Government of Uttar Pradesh (UP) to broaden its presence in the warehousing sector in North India.

### **Reliance seeks \$12.75 for CBM gas, ONGC wants \$9.35**

Billionaire Mukesh Ambani's Reliance Industries Ltd and state-owned Oil and Natural Gas Corporation (ONGC) are separately auctioning natural gas extracted from coal seams at prices linked to Brent crude oil price. Reliance is seeking a minimum USD 12.75 per million British thermal unit for coal bed methane (CBM) from a block in Shahdol district of Madhya Pradesh, while ONGC wants USD 9.35 for the same kind of fuel from North Karanpura in Jharkhand. Reliance has sought bids for sale of 0.65 million standard cubic meters per day from CBM block SP(West)-CBM-2001/1 for one year beginning April 1, 2023, the company's tender document showed. It asked bidders to quote a variable 'v' as a percentage of dated Brent crude oil price.



**CORPORATE ACTION BONUS / RIGHTS / STOCK SPLIT / DIVIDEND / FCCB / M&A / WARRANTS ETC.**

[illegible]

## Domestic Events

- India WPI Inflation for January 2023.

## Global Events

- Japan GDP Growth for Q4 2022.
- Japan Industrial Production for December 2022.
- The U.S. CPI Inflation for January 2023.
- Euro Area GDP Growth for Q4 2022.

Source of News : The content may have been taken from The Economic Times, Business Standard, Business Line, Mint and other leading financial newspapers and financial portals BSE,NSE, Bloomberg, Moneycontrol & others.



### **Analyst Certification:**

We /I, Jaydeb Dey Research Analyst(S) of SMIFS Limited (in short “SMIFS / the Company”), authors and the names subscribed to this Research Report, hereby certify that all of the views expressed in this Research Report accurately reflect our views about the subject issuer(s) or securities and distributed as per SEBI (Research Analysts) Regulations 2014. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this Research Report. It is also confirmed that We/I, the above mentioned Research Analyst(s) of this Research Report have not received any compensation from the subject companies mentioned in the Research Report in the preceding twelve months and do not serve as an officer, director or employee of the subject companies mentioned in the Research Report.

### **Terms & Conditions and Other Disclosures:**

SMIFS Limited is engaged in the business of Stock Broking, Depository Services, Portfolio Management and Distribution of Financial Products. SMIFS Limited is registered as Research Analyst Entity with Securities & Exchange Board of India (SEBI) with Registration Number – INH300001474.

SMIFS and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Research Analysts. SMIFS generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this Research Report have been prepared by SMIFS and are subject to change without any notice. The Research Report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of SMIFS Limited. While we would endeavor to update the information herein on a reasonable basis, SMIFS is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent SMIFS from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or policies of SMIFS, in circumstances where SMIFS might be acting in an advisory capacity to this company, or in certain other circumstances.

This Research Report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This Research Report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Securities as defined in clause (h) of section 2 of the Securities Contract Act, 1956, includes Financial Instruments, Currency and Commodity Derivatives. Though disseminated to all the customers simultaneously, not all customers may receive this Research Report at the same time. SMIFS will not treat recipients as customers by virtue of their receiving this Research Report. Nothing in this Research Report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this Research Report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. SMIFS accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this Research Report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document

to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. The information given in this report is as of date of this report and there can be no assurance that future results or events will be consistent with this information. The information provided in this report remains, unless otherwise stated, the copyright of SMIFS. All layout, design, original artwork, concepts and intellectual Properties remains the property and copyright of SMIFS and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the SMIFS.

SMIFS shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of SMIFS to present the data. In no event shall SMIFS be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the SMIFS through this report.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (a) Exchange Rates can be volatile and are subject to large fluctuations; (b) the value of currencies may be affected by numerous market factors, including world and notional economic, political and regulatory events, events in Equity & Debt Markets and changes in interest rates; and (c) Currencies may be subject to devaluation or government imposed Exchange Controls which could affect the value of the Currency. Investors in securities such as Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Since associates of SMIFS are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this Research Report.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may: (i) from time to time may have long or short positions in, and buy or sell the Securities, mentioned herein or (ii) be engaged in any other transaction involving such Securities and earn brokerage or other compensation of the Subject Company/ companies mentioned herein or act as an Advisor or Lender/Borrower to such Companies or have other potential/material Conflict of Interest with respect to any recommendation and related information and opinions at the time of the publication of the Research Report or at the time of Public Appearance.

SMIFS does not have proprietary trades but may at a future date, opt for the same with prior intimation to Clients/ Investors and extant Authorities where it may have proprietary long/short position in the above Scrip(s) and therefore should be considered as interested.

The views provided herein are general in nature and do not consider Risk Appetite or Investment Objective of any particular Investor; Clients/ Readers/ Subscribers of this Research Report are requested to take independent professional advice before investing, however the same shall have no bearing whatsoever on the specific recommendations made by the analysts, as the recommendations made by the analysts are completely independent views of the Associates of SMIFS even though there might exist an inherent conflict of interest in some of the stocks mentioned in the Research Report.

The information provided herein should not be construed as invitation or solicitation to do business with SMIFS.

SMIFS or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the Research Report as of the last day of the month preceding the publication of the Research Report.

SMIFS encourages independence in Research Report preparation and strives to minimize conflict in preparation of Research Report. Accordingly, neither SMIFS and their Associates nor the Research Analysts and their relatives have any material conflict of interest at the time of publication of this Research Report or at the time of the Public Appearance, if any.

SMIFS or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

SMIFS or its associates might have received any compensation from the companies mentioned in the Research Report during the period preceding twelve months from the date of this Research Report for services in respect of managing or co-managing public offerings, corporate finance, investment banking, brokerage services or other advisory service in a merger or specific transaction from the subject company.

SMIFS or its associates might have received any compensation for products or services other than investment banking or brokerage services from the subject companies mentioned in the Research Report in the past twelve months.

SMIFS or its associates or its Research Analysts did not receive any compensation or other benefits whatsoever from the subject companies mentioned in the Research Report or third party in connection with preparation of the Research Report.

Compensation of Research Analysts is not based on any specific Investment Banking or Brokerage Service Transactions.

The Research Analysts might have served as an officer, director or employee of the subject company.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may have been engaged in market making activity for the companies mentioned in the Research Report.

SMIFS may have issued other Research Reports that are inconsistent with and reach different conclusion from the information presented in this Research Report.

A graph of daily closing prices of the securities/commodities is also available at [www.nseindia.com](http://www.nseindia.com) and/or [www.bseindia.com](http://www.bseindia.com), [www.mcxindia.com](http://www.mcxindia.com) and/or [www.icex.com](http://www.icex.com).

SMIFS submit' s that no material disciplinary action has been taken on the Company by any Regulatory Authority impacting Equity Research Analysis activities in last 3 years.

This Research Report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SMIFS and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.



### Specific Disclosures

- SMIFS, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- SMIFS, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company.
- SMIFS, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months.
- SMIFS, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as director/officer/employee in the subject company
- SMIFS has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- SMIFS has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- SMIFS has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months.
- SMIFS has not received any compensation or other benefits from third party in connection with the research report.
- SMIFS has not engaged in market making activity for the subject company

Analyst holding in stock: **NO**

### Key to SMIFS Investment Rankings

Buy: Return >15%, Accumulate: Return between 5% to 15%, Reduce: Return between -5% to +5%, Sell: Return < -5%

### Contact us:

**SMIFS Limited.** (<https://www.smifs.com/>)

### Compliance Officer:

**Sudipto Datta,**

Vaibhav, 4 Lee Road, Kolkata 700020, West Bengal, India.

Contact No.: +91 33 4011 5401 /91 33 6634 5401

Email Id.: [compliance@smifs.com](mailto:compliance@smifs.com)